Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus ... May 23, 2024 — Treatment of autoimmune diseases ...

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

These factors included the Safety Of Estrogens In Lupus Erythematosus National Assessment–Systemic Lupus ... be related to study treatment, severe AEs and AEs leading to dose interruption or ...

Objective: To assess the reliability of Systemic Lupus Erythematosus Disease ... but a high SLEDAI-2000 score. The treatment of these patients with discordant BILAG-2004 and SLEDAI-2000 scores are ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

Columnist Candace Semien applies the concept of radical responsibility to managing lupus and other chronic health conditions.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...